OTCMKTS:AGNPF Algernon Pharmaceuticals (AGNPF) Stock Price, News & Analysis → Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad) Free AGNPF Stock Alerts $0.12 0.00 (0.00%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$0.12▼$0.1250-Day Range$0.06▼$0.1252-Week Range$0.04▼$0.19Volume8 shsAverage Volume16,391 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Algernon Pharmaceuticals alerts: Email Address Ad InvestorPlaceCrypto Pioneer Says: “The last crypto bull market has begun.”Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble.Click here if you’d like to learn more about these five cryptos… About Algernon Pharmaceuticals Stock (OTCMKTS:AGNPF)Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, pancreatic and small cell lung cancer, and acute lung injury in Canada and Australia. The company's pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in Phase 1 clinical trial for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which is in Phase 1 clinical trial for the treatment of strokes and traumatic brain injuries. The company was formerly known as Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in July 2015. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.Read More AGNPF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGNPF Stock News HeadlinesMay 21, 2024 | globenewswire.comAlgernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making ServicesApril 24, 2024 | globenewswire.comAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024April 11, 2024 | globenewswire.comAlgernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024April 3, 2024 | msn.comDMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial DesignApril 1, 2024 | globenewswire.comAlgernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead AssetMarch 28, 2024 | finance.yahoo.comAlgernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough TreatmentMarch 27, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - AGNMarch 27, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - AGNMarch 27, 2024 | proactiveinvestors.comAlgernon Pharmaceuticals closes $2M acquisition of its chronic cough research program by SeyltxMarch 27, 2024 | globenewswire.comAlgernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity PositionJanuary 31, 2024 | finance.yahoo.comAlgernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKDJanuary 11, 2024 | finance.yahoo.comAlgernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary FibrosisDecember 27, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Announces Increase to Private PlacementNovember 30, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLDNovember 22, 2023 | msn.comSeyltx acquires Algernon's chronic cough research program for $2M and 20% stakeNovember 22, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity PositionNovember 12, 2023 | uk.finance.yahoo.comAlgernon Pharmaceuticals Inc. (AGN.CN)November 8, 2023 | msn.comAlgernon gets Japanese patent notice of allowance for treatment of NASH with RepirinastNovember 8, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with RepirinastSeptember 9, 2023 | investing.comAlgernon Pharmaceuticals Inc Class A (AGN)September 6, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASHAugust 8, 2023 | benzinga.comDMT As A Treatment For Stroke? This Company Is Closer To Launching Its Phase 2 StudyAugust 8, 2023 | finance.yahoo.comAlgernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke StudyJuly 14, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory AgreementJune 27, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development ProgramSee More Headlines Receive AGNPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Algernon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:AGNPF CUSIPN/A CIK1642178 Webalgernonpharmaceuticals.com Phone604-398-4175FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Christopher J. Moreau (Age 59)CEO & Director Comp: $400.75kMr. James F. Kinley C.A. (Age 46)CPA, Chief Financial Officer Comp: $213.59kDr. Christopher Bryan Ph.D. (Age 41)Vice President of Research & Operations Comp: $220.95kKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors AGNPF Stock Analysis - Frequently Asked Questions How have AGNPF shares performed in 2024? Algernon Pharmaceuticals' stock was trading at $0.0535 on January 1st, 2024. Since then, AGNPF shares have increased by 117.3% and is now trading at $0.1163. View the best growth stocks for 2024 here. Are investors shorting Algernon Pharmaceuticals? Algernon Pharmaceuticals saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 22,600 shares, a drop of 7.8% from the April 30th total of 24,500 shares. Based on an average daily volume of 34,800 shares, the days-to-cover ratio is presently 0.6 days. View Algernon Pharmaceuticals' Short Interest. When did Algernon Pharmaceuticals' stock split? Algernon Pharmaceuticals shares split on the morning of Friday, March 3rd 2023. The 4-1 split was announced on Friday, March 3rd 2023. The newly minted shares were issued to shareholders after the closing bell on Friday, March 3rd 2023. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. How do I buy shares of Algernon Pharmaceuticals? Shares of AGNPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:AGNPF) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersA once-in-a-century investment opportunityStansberry ResearchThe #1 Crypto That You Don’t Own… YetCrypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersWrite this ticker symbol down…StocksToTradeYou won't believe what Citigroup just did to it's depositorsAmerican AlternativeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBill Clinton Backing Biden Replacement???The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Algernon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
